Trial Profile
A Phase III Randomized, Double-Blind,Placebo-Controlled, Multicenter Study of Icatibant for Subcutaneous Injection in Patients With Acute Attacks of Hereditary Angioedema (HAE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Icatibant (Primary)
- Indications Hereditary angioedema
- Focus Registrational; Therapeutic Use
- Acronyms FAST-3
- Sponsors Shire
- 23 Dec 2021 New source identified and integrated (European Clinical Trials Database EudraCT2009-015606-19).
- 01 Apr 2014 New trial record
- 19 Apr 2013